| Ident. | Authors (with country if any) | Title |
|---|
| 000023 (2009) |
Misato Hashizume [Japon] ; Yasushi Uchiyama [Japon] ; Naoto Horai [Japon] ; Naohisa Tomosugi [Japon] ; Masahiko Mihara [Japon] | Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production |
| 000048 (2012) |
Hiroki Wakabayashi [Japon] ; Masahiro Hasegawa [Japon] ; Yosuke Nishioka [Japon] ; Yukari Minami [Japon] ; Kusuki Nishioka [Japon] ; Akihiro Sudo [Japon] | Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure |
| 000089 (2013) |
Alfredo Adán [Espagne] ; Marina Mesquida [Espagne] ; Victor Llorenç [Espagne] ; Gerard Espinosa [Espagne] ; Blanca Molins [Espagne] ; Maria V. Hernández [Espagne] ; Laura Pelegrín [Espagne] | Tocilizumab treatment for refractory uveitis-related cystoid macular edema |
| 000154 (2011) |
Atsushi Kaneko [Japon] ; Daihei Kida [Japon] ; Kiwamu Saito [Japon] ; Masami Tsukamoto [Japon] ; Tomotaro Sato [Japon] | Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI |
| 000160 (2011) |
Susumu Nishiyama [Japon] ; Tetsushi Aita [Japon] ; Yasuhiko Yoshinaga [Japon] ; Hiroki Kishimoto [Japon] ; Michio Toda [Japon] ; Yoshiki Yoshihara [Japon] ; Shinya Miyoshi [Japon] ; Akira Manki [Japon] ; Shoji Miyawaki [Japon] | Proposing a method of regional assessment and a novel outcome measure in rheumatoid arthritis |
| 000169 (2015) |
Yanli Zhuang [États-Unis] ; Dick E. De Vries [Pays-Bas] ; Zhenhua Xu [États-Unis] ; Stanley J. Marciniak Jr. [États-Unis] ; Dion Chen [États-Unis] ; Francisco Leon [États-Unis] ; Hugh M. Davis [États-Unis] ; Honghui Zhou [États-Unis] | Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach |
| 000228 (2012) |
Tomoyuki Imagawa [Japon] ; Syuji Takei [Japon] ; Hiroaki Umebayashi [Japon] ; Kenichi Yamaguchi [Japon] ; Yasuhiko Itoh [Japon] ; Toshinao Kawai [Japon] ; Naomi Iwata [Japon] ; Takuji Murata [Japon] ; Ikuo Okafuji [Japon] ; Mari Miyoshi [Japon] ; Yasuhiro Onoe [Japon] ; Yoshifumi Kawano [Japon] ; Noriko Kinjo [Japon] ; Masaaki Mori [Japon] ; Neelufar Mozaffarian [États-Unis] ; Hartmut Kupper [Allemagne] ; Sourav Santra [Inde] ; Gina Patel [États-Unis] ; Shinichi Kawai [Japon] ; Shumpei Yokota [Japon] | Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan |
| 000306 (2013) |
Pavel Horák [République tchèque] ; Martina Skácelová [République tchèque] ; Karel Hejduk [République tchèque] ; Andrea Smržová [République tchèque] ; Karel Pavelka [République tchèque] | Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic—data from the ATTRA registry |
| 000343 (2007) |
Norihiro Nishimoto [Japon] ; Jun Hashimoto [Japon] ; Nobuyuki Miyasaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Shinichi Kawai [Japon] ; Tsutomu Takeuchi [Japon] ; Norikazu Murata [Japon] ; Désirée Van Der Heijde [Pays-Bas] ; Tadamitsu Kishimoto [Japon] | Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab |
| 000417 (2013) |
R. Ionescu ; C. Codreanu ; I. Ancuta ; A. Balanescu ; M. Parvu [Roumanie] ; D. Opris | AB0571 Efficacy of tocilizumab prescribed as first line biologic: A 48-week post marketing observational study in romanian rheumatoid arthritis patients (stone) - interim analysis |
| 000443 (2013) |
A. Oguma [Japon] ; S. Takahashi [Japon] ; T. Sawabe [Japon] | AB0513 (F) good outcomes at week 24 is lead by early introduction of tocilizumab and favorable treatment response up to week 12 |
| 000454 (2010) |
Takeshi Kuroda [Japon] ; Yoko Wada [Japon] ; Daisuke Kobayashi [Japon] ; Hiroe Sato [Japon] ; Syuichi Murakami [Japon] ; Masaaki Nakano [Japon] ; Ichiei Narita [Japon] | Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature |
| 000470 (2013) |
K. Hanami [Japon] ; K. Saito [Japon] ; H. Tasaka [Japon] ; Y. Tanaka [Japon] | FRI0190 CDAI is a predictor of physical function and bone destruction at week 52 in RA patients |
| 000530 (2011) |
Dimitrios Christidis [Royaume-Uni] ; Shaifali Jain [Royaume-Uni] ; Bhaskar Das Gupta [Royaume-Uni] | Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement |
| 000791 (2013) |
L. Xie ; M. C. Genovese [États-Unis] ; B. Zhu ; E. Edson-Heredia ; S. Banerjee | SAT0137 Early Clinical Improvements (Week 4) Predict Subsequent Clinical Response with Ixekizumab in Rheumatoid Arthritis Patients with Inadequate Response to tnf Inhibitors |
| 000804 (2013) |
T. Takeuchi [Japon] ; Y. Kaneko [Japon] ; T. Atsumi ; Y. Tanaka ; M. Inoh ; H. Kobayashi [Japon] ; K. Amano ; M. Miyata ; Y. Murakawa ; T. Fujii ; A. Kawakami ; H. Yamanaka ; K. Yamamoto ; N. Miyasaka [Japon] ; T. Mimori | OP0040 Adding Tocilizumab or Switching to Tocilizumab Monotherapy in RA Patients with Inadequate Response to Methotrexate: 24-Week Results from a Randomized Controlled Study (Surprise Study) |
| 000920 (2012) |
Laine H. Koch [États-Unis] ; Christle J. Layton [États-Unis] ; Monika Pilichowska [États-Unis] ; Miguel J. Stadecker [États-Unis] ; Orr Barak [États-Unis] | Paraneoplastic Pemphigus and Castleman’s Disease in the Setting of Herpes Simplex Virus Infection |
| 000A62 (2007) |
Katsuaki Kanbe [Japon] ; Kazuhiko Inoue [Japon] ; Yasuo Inoue [Japon] ; Yutaka Suzuki [Japon] | Histological changes in bone marrow after treatment of infliximab for rheumatoid arthritis |
| 000A74 (2010) |
V. B. Matthews [Australie] ; T. L. Allen [Australie] ; S. Risis [Australie] ; M. H. S. Chan [Australie] ; D. C. Henstridge [Australie] ; N. Watson [Australie] ; L. A. Zaffino [Australie] ; J. R. Babb [Australie] ; J. Boon [Australie] ; P. J. Meikle [Australie] ; J. B. Jowett [Australie] ; M. J. Watt [Australie] ; J.-O. Jansson [Suède] ; C. R. Bruce [Australie] ; M. A. Febbraio [Australie] | Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance |
| 000B44 (2012) |
W. Rigby [États-Unis] ; H. Tony [Allemagne] ; K. Oelke [États-Unis] ; B. Combe [France] ; A. Laster [États-Unis] ; C. A. Von Muhlen [Brésil] ; E. Fisheleva [Royaume-Uni] ; C. Martin [Royaume-Uni] ; H. Travers [Royaume-Uni] ; W. Dummer [États-Unis] | Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty‐eight–week randomized, double‐blind, placebo‐controlled, parallel‐group phase III trial |
| 000C06 (2013) |
Y. Tanaka ; M. Harigai ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Yamamoto [Japon] ; M. Kanazawa ; Y. Murakami ; T. Yoshinari [Japon] ; D. Baker [États-Unis] ; N. Miyasaka ; T. Koike [Japon] | FRI0177 52-week results of clinical, radiographic and pharmacokinetic assessments: Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy |
